A phase I single ascending dose (SAD) trial of SAGE 718 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs SAGE 718 (Primary)
- Indications Smith-Lemli-Opitz syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- 02 Nov 2017 Status changed from recruiting to completed, according to a Sage Therapeutics media release.
- 27 Apr 2017 Status changed from planning to recruiting according to a SAGE Therapeutics media release.
- 16 Nov 2016 New trial record